Advertisement
HUMAN DEVELOPMENT
Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway
Pooja Teotia, Matthew J. Van Hook, Dietmar Fischer, Iqbal Ahmad
Development 2019 146: dev178012 doi: 10.1242/dev.178012 Published 4 July 2019

ABSTRACT

The poor axon regeneration in the central nervous system (CNS) often leads to permanent functional deficit following disease or injury. For example, degeneration of retinal ganglion cell (RGC) axons in glaucoma leads to irreversible loss of vision. Here, we have tested the hypothesis that the mTOR pathway regulates the development of human RGCs and that its recruitment after injury facilitates axon regeneration. We observed that the mTOR pathway is active during RGC differentiation, and using the induced pluripotent stem cell model of neurogenesis show that it facilitates the differentiation, function and neuritogenesis of human RGCs. Using a microfluidic model, we demonstrate that recruitment of the mTOR pathway facilitates human RGC axon regeneration after axotomy, providing evidence that the recapitulation of developmental mechanism(s) might be a viable approach for facilitating axon regeneration in the diseased or injured human CNS, thus helping to reduce and/or recover loss of function.

INTRODUCTION

Axons regenerate poorly in the central nervous system (CNS), leading to functional deficits, often permanent, following brain disease or injury (Curcio and Bradke, 2018; Liu et al., 2011). Therefore, therapeutic facilitation of axonal regeneration is key to functional recovery. The optic nerve, which progressively degenerates in glaucoma leading to irreversible blindness (Almasieh et al., 2012), provides an accessible and facile model of axonal regeneration. The optic nerve contains the axons of retinal ganglion cells (RGCs), which connect the retina to higher centers in the brain for visual perception and therefore their degeneration leads to permanent vision loss. There is no effective treatment for RGC degeneration. Given this intractable situation, one of the approaches to negotiate the pathology of the disease is to understand the mechanism underlying RGC development, recapitulation of which may facilitate optic nerve regeneration, thus rescuing vision loss (Hilton and Bradke, 2017). Recently, several intrinsic factors have been identified that regulate axon regeneration (Curcio and Bradke, 2018; Liu et al., 2011; Moore and Goldberg, 2011). For example, deletion of negative regulators of the mTOR pathway, such as phosphate and tensin homolog (PTEN) or tuberous sclerosis 1 (TSC1), has been observed to promote robust axon regeneration in an optic nerve crush model (Park et al., 2008). Conversely, inhibition of the mTOR pathway by rapamycin abrogated PTEN/TSC1-mediated axon regeneration (Park et al., 2008). Subsequently, evidence has emerged supporting the influence of diverse factors, including the JAK-STAT3 pathway inhibitor SOCS3 (Smith et al., 2009), the Wnt pathway ligand Wnt10B (Tassew et al., 2017), the heterochronic gene Lin28a (Wang et al., 2018) and ubiquitin-like containing PHD ring finger (UHRF1) (Oh et al., 2018), on optic nerve regeneration. In each of these cases, it was observed that the mTOR pathway might have played some role in the regenerative process. Thus, current cumulative evidence suggests that the mTOR pathway is a key regulator of optic nerve regeneration and therefore a valid target for therapeutic RGC regeneration in glaucoma. However, these studies have been carried out in rodents; therefore, their clinical relevance in the progression of the disease and therapeutic regeneration remains poorly understood. Here, we have tested the hypothesis that the mTOR pathway regulates the development of human RGCs (hRGCs) and that its recruitment upon injury facilitates axon regeneration.

The mTOR pathway is a ubiquitous nutrient-sensing intracellular pathway that promotes growth and survival of cells mainly by regulating protein synthesis (Costa-Mattioli and Monteggia, 2013). It is suppressed in response to cellular stress and is associated with abnormalities in the developing nervous system. mTOR pathway activation involves inhibition of the TSC1/2 complex via the receptor-mediated activation of AKT kinases. The disinhibited mTOR complex 1 [raptor (RPTOR)-containing and rapamycin-sensitive] stimulates mRNA translation by activating ribosomal protein S6 and the elongation factor eIF4E. Inhibition of TSC1/2 activates the mTOR pathway and is, therefore, a practical approach to examine the influence of the mTOR pathway in development and injury (Choi et al., 2018; Huang et al., 2008; Park et al., 2008; Tee et al., 2016; Maiese et al., 2013). The mTOR pathway, which remains active during development, is downregulated in the adult brain and is further decreased after injury (Costa-Mattioli and Monteggia, 2013; Garza-Lombó and Gonsebatt, 2016; Lee, 2015; Morgan-Warren et al., 2013). Here, we demonstrate that the mTOR pathway constitutes an evolutionarily conserved regulatory mechanism underlying the development and regeneration of hRGCs. For example, the mTOR pathway was active during RGC differentiation and its experimental activation facilitated the differentiation of hRGCs from induced pluripotent stem cells (iPSCs). The positive influence of the mTOR pathway on differentiation included enhanced neuritogenesis and axon guidance and growth; hRGCs expressed a battery of axon guidance molecules and the response of their axons to netrin-DCC interactions was facilitated by the activated mTOR pathway. In contrast, inhibition of the pathway adversely affected hRGC differentiation, including neurite complexities and axon growth. The biochemical and morphological changes extended into hRGC physiology; the spontaneous action potentials and local networking and synaptogenesis facilitated by activating the mTOR pathway were abrogated when it was inhibited. Furthermore, we demonstrate that hRGCs possess the ability to regenerate their axons following chemical axotomy and that the mTOR pathway regulates the efficiency of axon regeneration. Together, our findings demonstrate the involvement of the mTOR pathway in RGC development and posit it as a valid target for examining the mechanism(s) underlying hRGC degeneration and the potential of therapeutic regeneration of the optic nerve in glaucoma. This information will also improve our understanding of axon regeneration in the CNS in general.

RESULTS

The mTOR pathway and hRGC development

To determine the involvement of the mTOR pathway in RGC differentiation, we first examined its status during retinal development. Because of the unavailability of human fetal tissues, initial experiments were carried out in rats with the rationale that results may be extrapolated across species because of the evolutionarily conserved developmental mechanisms of retinal histogenesis (Hoshino et al., 2017). Our primary readout for activated mTOR signaling was the detection of immunoreactivities corresponding to phospho-S6 (Ser240/244); activated mTOR phosphorylates p70 ribosomal S6 kinase (p70S6K), which in turn phosphorylates and activates S6, a ribosomal protein that regulates protein translation (Saxton and Sabatini, 2017). Our secondary readout was the expression of transcripts and immunoreactivities corresponding to the TSC2, which inhibits the mTOR1 complex and correlates negatively with activation of the mTOR pathway (Saxton and Sabatini, 2017). We observed that phospho-S6 (p-S6) staining was robust at stages representing both early [embryonic day (E) 14] and late (E18) histogenesis but was undetectable in adult retina, suggesting active mTOR during retinal development and its cessation upon maturity (Fig. 1A-C). In both E14 and E18 retina, p-S6 staining was confined to the inner retina, where nascent RGCs, characterized by the expression of BRN3A (POU4F1), were localized (Fig. 1A-C). Quantification of immunoreactive cells revealed that the majority of p-S6-positive cells (p-S6+) co-expressed BRN3A in E14 and E18 retina and that p-S6+ BRN3A+ cells were undetectable in the adult retina (Fig. 1D), indicating a correlation between mTOR activity and RGC development. Such correlation was further shown by the temporal expression patterns of TSC2 protein (Fig. 1E) and transcripts (Fig. 1F), which were inverse of those for the transcriptional regulators of RGC differentiation, Atoh7, and Brn3B (Fig. 1G,H). Next, to determine if this correlation was conserved during human retinal development, we curated RNA sequencing data obtained from different stages of fetal and adult human retina (Hoshino et al., 2017). We found that the expression patterns of TSC2 and of ATOH7 and BRN3B in the developing human retina were similar to those observed in rats (Fig. 1I-K).

Fig. 1.
Fig. 1.

mTOR pathway activities during retinal development and in the adult retina. (A-C) Immunohistochemical analysis of sections of the rat retina at E14, E18, and adult stages showed RGCs co-expressing p-S6 and BRN3A immunoreactivities. Arrowheads indicate BRN3A+ RGCs with (E14 and E18) or without (adult) p-S6 immunoreactivities. (D) Quantification of cells revealed that the proportion of p-S6+/BRN3a+ RGCs decreased in adult versus embryonic stages. (E) Western blot and densitometry analysis of cell lysates obtained from E14, E18 and adult retina revealed a temporal increase in the expression of TSC2. (F-H) qPCR analysis of RNA from E14, E18 and adult retina revealed a temporal increase and decrease in the expression of Tsc2 and Atoh7 and Brn3B transcripts, respectively. (I-K) Normalized gene count of corresponding transcripts from curated RNA sequencing datasets (Gene Expression Omnibus accession number GSE104827) for human fetal retina samples (D53 to D132) spanning distinct stages of development showed temporal expression patterns of TSC2 and ATOH7 and BRN3B that were similar to those observed in the rat. Quantification of immunoreactive cells was performed on 6-7 sections/group in 5-6 randomly selected areas. Values are expressed as mean±s.e.m. from 2-3 independent biological replicates (Student's t-test). Scale bar: 50 µm.

Together, these observations suggest that the conserved decline in mTOR pathway activity, indicated by the temporal activation of TSC1/TSC2 expression, might be functionally correlated with hRGC differentiation. This notion was tested in the iPSC model of human neurogenesis. We have recently demonstrated that both rodent and human pluripotent cells can be directly differentiated along the RGC lineage by chemical recruitment of RGC developmental mechanisms (Teotia et al., 2017a). The efficiency of RGC generation was ∼40% (Fig. S1A,B). Human iPSCs were differentiated into RGCs when the mTOR pathway was activated by lentivirus-mediated transduction of TSC2-shRNA (hRGCTSC2-shRNA) or repressed by the exposure of cells to rapamycin, an inhibitor of the mTOR1 complex (Saxton and Sabatini, 2017) (hRGCRapamycin+; Fig. 2A). Controls included cells transduced with the empty lentivirus (hRGCControl). The transduction efficiency was ∼80% (Fig. S1C). To address the concern that the results might be due to the function of pluripotent cells, experiments were carried out in parallel with retinal progenitor cells (RPCs) enriched from the developing rat retina (Fig. S2A). The transduction efficiency of TSC2-shRNA lentivirus in rat RPCs was ∼70% (Fig. S1C).

Fig. 2.
Fig. 2.

Influence of the mTOR pathway on hRGC differentiation. (A) Schematic of lentivirus-mediated transduction of TSC2-shRNA in the neural rosette (NR) and their directed differentiation into hRGCs. (B) qPCR analysis of RNA in hRGCs showed a significant decrease in TSC2 transcript levels in hRGCs transduced with TSC2-shRNA lentivirus versus controls. (C,D) To determine the extent of mTOR signaling in hRGCs transduced with TSC2-shRNA/control lentivirus or exposed to rapamycin during differentiation, relative levels of p-S6 and S6 were determined by western blot analysis. Levels of p-S6 were increased and decreased in hRGCTSC2-shRNA and hRGCRapamycin groups, respectively, compared with controls, whereas those of S6 remained unchanged. (E-H) Immunocytochemical analysis of cells in three treatment groups revealed that the proportion of GFP+ (transduced cells) and β-tubulin+ cells (nascent RGCs) significantly increased and decreased in hRGCTSC2-shRNA and hRGCRapamycin groups, respectively, compared with control. (I-L) The results above were supported by a significant increase and decrease in the proportion of GFP+p-S6+ cells in hRGCTSC2-shRNA and hRGCRapamycin groups, respectively, versus controls. (M-P) Similar analysis to quantify S6+ cells revealed an unchanged proportion of GFP+S6+ cells across the groups, demonstrating the specificity of the perturbation of the mTOR pathway. Quantification of immunoreactive cells was performed using 4-5 coverslips/group in 5-6 randomly selected areas. Values are expressed as mean±s.e.m. (Student's t-test). Experiments were carried out three times in triplicate per group for in vitro perturbations. Arrowheads indicate GFP+ cells displaying cell type-specific immunoreactivities. Scale bar: 50 µm.

Transduction of TSC2-shRNA lentivirus led to significant silencing of both TSC2 protein and transcript expression in both human (h)iPSC- (Fig. 2B, Fig. S3) and rat RPC- (Figs S3B and S4) derived RGCs, compared with those transduced with control lentivirus. This result was accompanied by a significant increase in the levels of p-S6 in hRGCTSC2-shRNA groups versus controls (Fig. 2C). In contrast, exposure to rapamycin led to a significant decrease in p-S6 levels in hRGCRapamycin groups, versus controls (Fig. 2C). Levels of S6 remained unchanged across the groups (Fig. 2D). That the effect of rapamycin was not due to its cytotoxicity was revealed by the absence of significant changes between all groups in a cell survival assay (Fig. S5). Together, these results demonstrated that TSC2-shRNA and rapamycin facilitated and inhibited the mTOR pathway, respectively, in RGCs generated from hiPSCs and rat RPCs. Next, we examined the consequence of perturbation of mTOR signaling on RGC generation. Quantification of hRGCs (GFP+β-tubulin+ cells) revealed that, in comparison to controls, there was a significant increase (87.55±1.97% versus 76.00±0.57%, P=0.0049) and decrease (30.55±2.77% versus 76.00±0.57%, P≤0.0001) in the proportions of these cells in hRGCTSC2-shRNA and hRGCRapamycin groups, respectively (Fig. 2E-H). That the mTOR pathway specifically influenced the generation of hRGCs and E18 RGCs was further corroborated by similar changes in the proportion of cells expressing the RGC regulator BRN3A (GFP+BRN3A+ cells) as that of GFP+β-tubulin+ cells in response to a perturbation in the mTOR pathway (Figs S6 and S7). The results obtained by immunocytochemical analysis was consistent with the readout of mTOR pathway activities at the single cell level; there was a significant increase and decrease in the proportion of p-S6+GFP+ cells in hRGCTSC2-shRNA and hRGCRapamycin groups, respectively, compared with controls (Fig. 2I-L), whereas the proportion of S6+GFP+ cells remain unchanged across the group (Fig. 2M-P). Similar effects of mTOR pathway perturbations were observed on the generation of RGCs from rat RPCs in response to perturbation of the mTOR pathway (Fig. S2).

The mTOR pathway and hRGC neuritogenesis

It has been observed that the mTOR pathway regulates dendritic morphology and axon formation and projection of rodent RGCs (Morquette et al., 2015; Nie et al., 2010). To test the premise that the mTOR pathway regulates neuritogenesis and axon growth we first determined the complexities of neurites elaborated by RGCs by Sholl analysis (Sholl, 1953). This and all subsequent experiments were done on hRGCs. The analysis demonstrated that both the number of intersections and distance of the processes from the soma were significantly greater in cells belonging to the hRGCTSC2-shRNA groups, compared with controls (Fig. 3A-D). In contrast, the number of intersections and distance of the processes from the soma were significantly reduced in the hRGCRapamycin groups versus controls (Fig. 3A-D). These observations suggest that the mTOR pathway has a significant impact on the generation and complexities of neurites, which might involve the recruitment of factors that regulate the growth and guidance of the neurites (Nie et al., 2010). To test this premise, we first examined the expression of growth regulatory factors – the Kruppel-like family of transcription factors (KLFs) and SRY-related HMG-box transcription factor 11 (SOX11) (Li et al., 2018; Moore and Goldberg, 2011) (Fig. 4). Fifteen of the 17 known KLFs are expressed in the rodent retina and their expression patterns, particularly that of KLF4, KLF6, KLF7 and KLF9, are associated with the developmental decline in axonal growth of RGCs after birth (Moore et al., 2009; Moore and Goldberg, 2011). For example, KLF4 and KLF9, expression of which increases postnatally, and that of KLF6 and KLF7, which decreases postnatally, repress and facilitate axonal growth, respectively, in an experimental model (Moore et al., 2009; Moore and Goldberg, 2011). Sox11 is involved in RGC differentiation and optic nerve development and has been observed to promote regeneration of RGCs in rodents (Li et al., 2018; Norsworthy et al., 2017). Quantification of specific transcripts following perturbation of the mTOR pathway in hRGCs revealed that expression of KLF6 and SOX11 increased and of KLF4 decreased in hRGCTSC2-shRNA groups compared with controls (Fig. 4A-C). In contrast, the expression of KLF4 was upregulated and that of KLF6 and SOX11 attenuated when the mTOR pathway was inhibited, suggesting a functional correlation between the mTOR pathway and expression of these growth regulatory factors during neuritogenesis (Fig. 4A-C). Second, we examined the expression of genes encoding guidance molecules that regulate the pathfinding of RGC axons, specifically those involved in intra-retinal guidance (de la Torre et al., 1997) (e.g. DCC), guidance at the optic chiasm (Erskine et al., 2000) (e.g. ROBO2), retinotopic connection in the superior colliculus (Hindges et al., 2002) (e.g. EPHB3), and general growth of the processes (Kruger et al., 1998) (e.g. GAP43). We observed significantly higher levels of transcripts corresponding to GAP43, ROBO2, DCC, EPHB3 and EPHA4 in cells belonging to the hRGCTSC2-shRNA groups than in controls (Fig. 4D-H). Levels of these transcripts, except for DCC, remained unchanged in the hRGCRapamycin group, compared with controls. To address the possibility that the lack of influence of rapamycin on transcript levels was due to their global measurement, which might not detect small but significant changes in a subpopulation of cells, we quantified single hRGCs, expressing immunoreactivities corresponding to GAP43 (Fig. S8A-D) and ROBO2 (Fig. S8E-H) in the three groups. A significant increase and decrease in GFP+GAP43+ and GFP+ROBO2+ cells were observed in the hRGCTSC2-shRNA and hRGCRapamycin groups, respectively, compared with controls, demonstrating that perturbation of the mTOR pathway affects the expression of guidance receptors/molecules. Lastly, in order to determine whether the mTOR pathway affected guidance molecule-dependent hRGC axon growth, we examined whether or not hRGCs responded to guidance through DCC-netrin interactions, which is essential for intra-retinal guidance and navigation through the optic nerve head (de la Torre et al., 1997). We observed an extensive elaboration of filopodia in growth cones of hRGCs exposed to netrin, compared with controls (Fig. 5A-D). The extended filopodia collapsed when exposed to netrin pre-incubated with DCC antibodies, demonstrating the specificity of netrin's effects on the morphology and motility of the growth cones.

Fig. 3.
Fig. 3.

Influence of the mTOR pathway on hRGC neurites. (A-C) Representative images of hRGCs in hRGCControl, hRGCTSC2-shRNA and hRGCRapamycin groups. (D) Sholl analysis of cells revealed the complexities of neurites and their lengths in hRGCs in the three groups defined above. GFP+ cells, separate from clumps, in 3-5 coverslips were subjected to Sholl analysis. Values are expressed as mean±s.e.m. from three independent biological replicates (Student's t-test). Scale bar: 50 μm.

Fig. 4.
Fig. 4.

Influence of the mTOR pathway on the expression of regulators of neurites, and axon pathfinding. (A-D) qPCR analysis of RNA in hRGCs in three treatment groups revealed that the expression of transcripts corresponding to positive regulators of axon growth (KLF6, SOX11 and GAP43) was significantly increased in hRGCTSC2-shRNA groups, compared with controls, but was abrogated in the hRGCRapamycin group. The patterns of expression of KLF4, a negative regulator of axon growth, was inverse that of KLF6, SOX11 and GAP43. (E-H) qPCR analysis of RNA in hRGCs in three treatment groups revealed that the expression of transcripts corresponding to axon guidance molecules (ROBO2, DCC, EPHB3 and EPHA4) significantly increased in hRGCTSC2-shRNA groups, compared with controls, but was abrogated in the hRGCRapamycin group. Values are expressed as mean±s.e.m. from three independent biological replicates (Student's t-test).

Fig. 5.
Fig. 5.

Influence of axon guidance molecules on hRGC axon growth cones. (A-D) Confocal images of hRGC growth cones in the presence of IgG (control), Netrin-1+IgG, and Netrin-1+DCC. The number of filopodia significantly increased in the presence of Netrin-1 versus IgG and Netrin-1+DCC control groups. (E) Time-lapse images of a representative hRGC axon in controlled conditions. (F) Time-lapse images of the same axon exposed to netrin-1. Dashed line indicates the boundary used for quantification of forward advancement of the growth cone. (G) Quantification of axon growth over a 25 min period in the presence and absence of Netrin-1. Values are expressed as mean±s.e.m. (Student's t-test; *P<0.05, **P<0.01; ns, not significant). Experiments were carried out in triplicates per group. Scale bars: 20 μm.

Next, we examined whether activated growth cones resulted in the growth of axons. Time-lapse examination of the hRGCs' axons demonstrated a significant increase in their length when exposed to 50 ng/ml of netrin, compared with controls, over time (Fig. 5E-G). However, the difference between the experimental and control groups disappeared after 25 min. Having ascertained that hRGC growth cones respond to netrin, we examined the effect of the mTOR pathway on the efficiency of the growth of hRGC axons in the presence of netrin. This experiment was carried out in a microfluidic device in which the hRGC axons (characterized by the co-expression of Tau1/SM132) are segregated from the soma in the microgrooves of the device (Fig. S9). We observed a three-fold increase (3.61±0.84, P=0.0151) in the number of axons that reached the axonal chambers of the microfluidic devices in hRGCTSC2-2shRNA groups compared with controls (Fig. 6). hRGCs exposed to rapamycin failed to extend axons in the microgroove (data not shown). Together, these results demonstrated that hRGCs were growth and guidance competent; they express guidance molecules and display a conserved response to them, facilitated by the mTOR pathway.

Fig. 6.
Fig. 6.

Influence of the mTOR pathway on hRGC axon growth. (A) Schematic of experimental design to demonstrate the influence of activated mTOR signaling on hRGCs growth cones in response to Netrin-1. Netrin-1 was added to hRGC medium in the axon chamber. (B-D) Images show the number of GFP+ and Alexa Fluor 594-phalloidin-stained axons in the axonal chamber in the presence and absence of netrin-1. There was ∼3-fold increase in the number of axons in the axonal chamber in the presence of netrin-1 than in controls. Values are expressed as mean±s.e.m. (Student's t-test). Experiments were carried out in triplicate per group. Scale bar: 50 μm. μG, microgrooves.

The mTOR pathway and human RGC function and network

Next, we were interested to know whether the mTOR pathway's influence on hRGC differentiation included their functional features and maturity. To address this, we performed whole-cell voltage- and current-clamp recordings to measure voltage-gated currents, passive membrane properties, and spiking behavior. In voltage-clamp, a series of depolarizing voltage steps (−70 to +40 mV in 10 mV increments) revealed fast inward Na+ currents (INa) and slower outward K+ currents (IK) (Fig. 7A-C). The amplitude of INa peaked at −20 mV and was similar in hRGCControl and hRGCTSC2-shRNA (4.1±0.5 nA in hRGCControl, n=14; 4.3±0.6 nA in hRGCTSC2-shRNA, n=14), but was dramatically reduced in hRGCRapamycin (1.7±0.3 nA, n=14, P=0.001). In current-clamp recordings, we monitored resting membrane potential (Vrest) and spontaneous spiking behavior (Fig. 7D-G). Both hRGCControl and hRGCRapamycin were fairly depolarized at rest (hRGCControl: −31±2 mV, n=7; hRGCRapamycin: −37±3 mV, n=7) and were not firing action potentials, presumably due to Na+ channel inactivation. hRGCTSC2-shRNA, in contrast, were less depolarized (Vrest=−45±4 mV, n=9) and fired regular spontaneous action potentials at 0.9±0.2 Hz. We next applied a hyperpolarizing DC current to maintain Vrest at approximately −75 mV and recorded spiking behavior in response to depolarizing current injections (+10 to +70 mV, 500 ms). All groups fired fewer action potentials at very strong depolarizing injections due to Na+ channel inactivation and depolarization block (Fig. 7F,G). hRGCTSC2-shRNA had a higher peak number of evoked spikes at +20 pA (3.9±0.6, n=9) and hRGCRapamycin fired 2.8±0.6 (n=9). hRGCRapamycin had a significantly elevated input resistance (2.4±0.2 GΩ, n=14) relative to hRGCControls (1.0±0.1 GΩ, n=11; P=0.00005) whereas input resistance for hRGCTSC2-shRNA was not significantly different from controls (hRGCTSC2-shRNA: Rin=1.3±0.2 GΩ, n=11; P=0.19) The differences in spiking patterns are likely the result of both the lower Na+ current amplitude in hRGCRapamycin and their relatively high input resistance, which means that depolarizing current injections will more readily move the membrane potential to spike threshold and, at higher stimulus strengths, to depolarization block.

Fig. 7.
Fig. 7.

Influence of the mTOR pathway on hRGC physiology. (A) Phase contrast image of a patch pipette attached to the membranes of hRGCControl, hRGCTSC2-shRNA and hRGCRapamycin. Scale bars: 10 μm. (B) Whole-cell voltage-clamp recording revealed fast inward and delayed outward currents evoked by depolarizing steps (−70 to +40 mV) from a holding potential of −80 mV. (C) The fast inward and outward currents showed current-voltage relationships typical of voltage-gated sodium (INa) and delayed potassium (IK) currents, respectively, in all groups (n=14 cells per group). (D) Current-clamp traces recorded in the absence of current injection (I=0 recording mode) showing resting membrane potential and spontaneous spiking. The hRGCTSC2-shRNA cell was slightly hyperpolarized and spiking whereas the Vrest for hRGCControl and hRGCRapamycin cells were more depolarized and did not spike due to depolarization block. (E) Quantification of spontaneous spike frequency showing that hRGCTSC2-shRNA cells maintained spontaneous spiking whereas hRGCControl and hRGCRapamycin cells were comparatively silent. (F) Whole-cell current-clamp recordings of responses to depolarizing and hyperpolarizing current injections (−40 to +70 pA) to measure passive membrane properties and spiking behavior. DC current was applied to maintain Vrest near −75 mV. (G) Intensity-response plots showing that hRGCTSC2-shRNA were more excitable than hRGCControl or hRGCRapamycin. Spiking declined at stronger stimulus intensities due to depolarization block.

We next used calcium imaging to measure spontaneous Ca2+ transients to examine further the effects of mTOR signaling on the spontaneously active neural network in culture (Teotia et al., 2017b) (Fig. 8). Cell fate specification leads to expression of a select combination of ion channels, which generate particular patterns of spontaneous activities, accompanied by transient elevations of intracellular calcium concentrations that sustain a specific neural network (Spitzer et al., 2004). We found that cells in hRGCTSC2-shRNA and hRGCRapamycin groups displayed significantly higher and lower spontaneous Ca2+ transients versus cells in the hRGCControl group, respectively (Fig. 8A-C). Spontaneous spikes were retained in cell bodies and did not propagate to processes in cells in the hRGCRapamycin group compared with cells in the hRGCTSC2-shRNA and control groups (Fig. 8A-C, upper panels). Moreover, the mean amplitude of spontaneous Ca2+ transients was significantly larger in cells in the hRGCTSC2-shRNA group than in controls (Fig. 8D). In contrast, exposure of cells to rapamycin almost erased the mean amplitude of spontaneous Ca2+ transients, compared with controls. Next, to determine the mechanism underlying the influence of mTOR signaling on the local neural network, we quantified the expression of the presynaptic protein synaptophysin (Fig. S10A-D) and the postsynaptic protein PSD95 (DLG4) (Fig. S10E-H) in response to a perturbation in the mTOR pathway. We observed that the proportion of cells expressing synaptophysin or PSD95 in the hRGCTSC2-shRNA group was significantly higher than in the hRGCControl group. In contrast, the proportion of these cells in the hRGCRapamycin group was significantly lower than in the hRGCControl group (Fig. S10D,H). Together, these observations suggest that mTOR signaling facilitates functional maturation of RGCs, including the formation of spontaneously active local neural networks, presumably through synaptogenesis.

Fig. 8.
Fig. 8.

Influence of the mTOR pathway on spontaneously active hRGC neural network. (A-C) Representative traces show that spontaneous calcium transients were higher in hRGCTSC2-shRNA groups than in controls. These were almost undetectable in hRGCRapamycin groups. The upper windows in each figure represent the change in fluorescent intensity, corresponding to calcium transients, at each time point (x-axes). Dashed line outlines a single time point in a particular cell. (D) The mean amplitude and frequency of spontaneous calcium spike increased and decreased significantly in hRGCTSC2-shRNA and hRGCRapamycin groups, respectively, compared with controls. Experiments were carried out in triplicate per group.

The mTOR pathway and hRGC axon regeneration

In the rodent retina, activation of the mTOR pathway has been found to promote axon regeneration in the optic nerve crush model (Park et al., 2008). Whether or not this premise holds true for hRGCs was tested in the microfluidic model of hRGC axotomy, established in our lab (Fig. 9A,B). Here, hRGC axons that had reached the axon chamber were axotomized by exposure to a detergent and allowed to regenerate back into the axon chamber, where the numbers of axons from lentivirus-transduced-hRGCs were quantified. hRGC axons degenerated within 10 min of exposure to the detergent. Remnants of degenerated axons in the axon chamber were removed by the wash, and culture medium restored in the chamber. The axons began to regenerate back into the axon chamber within 48 h (Fig. 9B), and their quantification in hRGCTSC2-shRNA and control groups was conducted 5 days after axotomy, following labeling with CTB-CY3 to account for only those axons that were transduced (GFP+) (Fig. 9C-E). Quantification of GFP+CY3+ axons revealed that the proportion of axons in the axonal chambers was significantly higher in the hRGCTSC2-shRNA group, compared with controls (75.33±1.76% versus 45.40±2.70%, P=0.0008) (Fig. 9C,D,F). The number of axons in the hRGCTSC2-shRNA group fell significantly below that of controls when rapamycin was added to the culture medium (Fig. 9C,E,F). A recent study reported that alpha-RGCs (αRGCs) preferentially survive axotomy and selectively regenerate in mice owing to high endogenous levels of mTOR activity (Duan et al., 2015). We have determined the range of subtypes generated from human iPSCs (P.T. and I.A., unpublished observations). αRGCs are present among different RGCs subtypes (Fig. S11). Therefore, we examined whether or not hiPSC-derived αRGCs account for the regeneration in response to the activation of the mTOR pathway. We observed that the majority of regenerating axons (GFP+CY3+) also expressed immunoreactivities corresponding to neurofilament SMI32, an αRGC marker (Duan et al., 2015; Krieger et al., 2017; Lin et al., 2004) (Fig. 9G), suggesting that hiPSC-derived αRGCs are responsive to mTOR pathway-mediated regeneration. Next, to confirm that other pathways implicated in the regeneration of axons on rodent are functional in hRGCs and may be interactive with the mTOR pathway, we examined whether recruitment of the JAK-STAT3 pathway alone (Fischer, 2017) or in combination with the mTOR pathway (Leibinger et al., 2016; Park et al., 2008; Smith et al., 2009) could facilitate hRGC axon regeneration. It has been recently demonstrated that hyper-interleukin-6 (hIL6), a designer cytokine that directly binds to the signaling receptor GP130 (IL6ST) without the need of additional co-receptors to activate the JAK-STAT3 pathway, promotes RGC neurite growth in vitro and axon regeneration in the optic nerve crush model (Fischer, 2017). hRGCs were transduced with Baculovirus-hIL-6/Baculovirus-GFP control virus and subjected to axotomy and regeneration protocol as described above (Fig. 10). Quantification of GFP+CY3+ axons revealed that the proportion of axons in the axonal chambers was significantly higher in the hRGChIL-6 group, compared with controls (71.00±2.43% versus 49.87±6.23%, P=0.0342) following axotomy (Fig. 10A,B,D). The number of axons in the hRGChIL-6 group decreased significantly to the levels observed in controls when AG490, an inhibitor of the JAK-STAT3 pathway (Leibinger et al., 2016), was added to the culture medium, demonstrating a positive influence of the JAK-STAT3 pathway on hRGC axon regeneration (Fig. 10A,C,D). The lack of abrogation of regeneration beyond the levels in control was likely due to the low concentration (10 µM) of AG490, which was used to prevent cytotoxicity (Yadav et al., 2005). Furthermore, we observed that the proportion of axons in the axon chamber following axotomy was significantly higher in hRGCs co-transduced with TSC2-shRNA lentivirus and hIL-6 baculoviruses than those transduced with either the former or latter alone, demonstrating an additive effect of the mTOR and JAK-STAT3 pathways on axon regeneration (Fig. 11A,B,D,E). The number of regenerating axons in double-transduced RGCs decreased significantly in the presence of rapamycin+AG490, compared with controls (Fig. 11A,C,D). Together, these observations suggest that hRGCs axons display regenerative capacity, which could be influenced by the mTOR pathway alone or in concert with the JAK-STAT3 pathway.

Fig. 9.
Fig. 9.

Influence of the mTOR pathway on hRGC axon regeneration following chemical axotomy. (A) Schematic of a microfluidic model of hRGCs chemical axotomy and regeneration, where hRGCs are generated in the soma chamber of a microfluidic device. Axons traversing through the microgrooves are axotomized by saponin, followed by their regeneration back into the axon chamber. (B) Fluorescent images of GFP+ axons, isolated in the microgrooves, are displayed before (left; arrows) and after (middle) axotomy, and following regeneration (right; arrowheads indicate regenerated axons) after 5 days post-axotomy. (C-F) hRGCs in three groups [hRGCControl(C); hRGCTSC2-shRNA (D) and hRGCTSC2-shRNA+Rapamycin (E)] were subjected to axotomy and regeneration, as described above. Following regeneration, axons were labeled retrogradely with CTB-CY3 to detect regeneration in GFP+ axons. Arrowheads indicate regenerated axons. A robust regeneration (∼2-fold), as ascertained by the increase in the number of GFP+CY3+ axons in the axon chamber post-axotomy, was observed in hRGCTSC2-shRNA groups, compared with controls (F). The number of GFP+CY3+ axons post-axotomy was significantly decreased compared with controls when cells in the hRGCTSC2-shRNA groups were exposed to rapamycin (F). (G) Immunocytochemical analysis of regenerated hRGCTSC2-shRNA RGC axons (GFP+CY3+) expressing immunoreactivities corresponding to the αRGC marker SMI32. GFP+CY3+ axons were counted blind in the somal chambers of the microfluidics (µF) devices. Arrows indicate soma and arrowheads indicate axon of a regenerated cell expressing SMI32. Values are expressed as mean±s.e.m. from three independent biological replicates (Student's t-test). Scale bars: 50 µm.

Fig. 10.
Fig. 10.

Influence of the JAK-STAT3 pathway on hRGC axon regeneration. (A-D) hRGCs in three groups [hRGCControl (A); hRGChIL6 (B) and hRGChIL6+AG490 (C)] were subjected to axotomy and regeneration, as described in Fig. 9. Following regeneration, axons were labeled retrogradely with CTB-CY3 to detect regeneration in GFP+ axons. Axon regeneration (∼2-fold), as ascertained by the increase in the number of GFP+CY3+ axons in the axon chamber post-axotomy, was observed in the hRGCTSC2-hIL6 group, compared with controls (D). The number of GFP+CY3+ axons post-axotomy was significantly decreased, compared with the hRGChIL6 group when cells in that group were exposed to AG490 (D). GFP+CY3+ axons were counted blind in the somal chambers of the microfluidic devices. Arrowheads indicate regenerated axon. Values are expressed as mean±s.e.m. (Student's t-test) from three independent biological replicates. Scale bar: 50 µm. group, compared with controls (D). The number of GFP+CY3+ axons post-axotomy was significantly decreased, compared with controls when cells in the hRGCTSC2-shRNA+hIL6 group were exposed to rapamycin+AG490 (D). Values are expressed as mean±s.e.m. from three independent biological replicates. (Student's t-test). Scale bar: 50 µm.

Fig. 11.
Fig. 11.

Combined influence of the mTOR and JAK-STAT3 pathways on hRGC axon regeneration. (A-D) hRGCs in three groups [hRGCControl (A); hRGCTSC2-shRNA+hIL6 (B) and hRGCTSC2-shRNA+hIL6+Rapamycin+AG490 (C)] were subjected to axotomy and regeneration, as described in Fig. 9. Following regeneration, axons were labeled retrogradely with CTB-CY3 to detect regeneration in GFP+ axons. Axon regeneration (∼2-fold), as ascertained by the increase in the number of GFP+CY3+ axons in the axon chamber post-axotomy, was observed in the hRGCTSC2-shRNA+hIL6 group, compared with controls (D). The number of GFP+CY3+ axons post-axotomy was significantly decreased, compared with controls when cells in the hRGCTSC2-shRNA+hIL6 group were exposed to rapamycin+AG490 (D). A comparison of the number of regenerated axons in hRGCTSC2-shRNA, hRGChIL6 and hRGCTSC2-shRNA+hIL6 groups revealed a small but significant additive effect in the hRGCTSC2-shRNA+hIL6 group versus the other two (E). Values are expressed as mean±s.e.m. from three independent biological replicates. (Student’s t-test). Scale bar: 50 µm.

DISCUSSION

The mTOR pathway is a ubiquitous nutrient-sensing intracellular pathway that promotes growth and survival mainly by regulating protein synthesis (Costa-Mattioli and Monteggia, 2013; Sarbassov et al., 2005; Swiech et al., 2008; Saxton and Sabatini, 2017). It is suppressed in response to cellular stress and is associated with abnormalities in the developing nervous system (Costa-Mattioli and Monteggia, 2013; Swiech et al., 2008). That the mTOR pathway is intrinsically involved in CNS axon regeneration was demonstrated when genetic deletion of PTEN in adult RGCs was observed to promote robust regeneration of their axons after optic nerve crush (Park et al., 2008). The abrogation of PTEN deletion-mediated regeneration in the presence of rapamycin and its restoration upon the genetic deletion of TSC2, further determined that RGC axon regeneration is facilitated when the mTOR pathway is activated (Park et al., 2008; Choi et al., 2008). Subsequently, similar approaches to perturb the pathway demonstrated its involvement elsewhere in the CNS, including in the regeneration of axons in the corticospinal tracts (Du et al., 2015; Liu et al., 2010; Zukor et al., 2013). We demonstrate that, much like in rodents, the mTOR pathway plays an important role in the development of hRGCs (Choi et al., 2019) and regeneration of their axons (Park et al., 2008), and is therefore an important molecular target for establishing a disease model of glaucomatous degeneration and therapeutic RGC regeneration. This premise is supported by the following observations. First, the mTOR pathway activity was temporally correlated with RGC differentiation in both rat and human retina, suggesting a conserved relationship between the pathway and RGC development. Second, the efficiency of hRGC differentiation was low, their morphology abnormal in terms of neurites, and function compromised when the mTOR pathway was inhibited during differentiation. These abnormalities, compared with controls, were rescued when the mTOR pathway was experimentally activated, suggesting that, regardless of specific mechanisms for lineage-specific differentiation, a basal level of the mTOR activity within the differentiating RPCs may be essential for the optimal differentiation of hRGCs. This notion is supported by observations that in rodents the mTOR pathway regulates (1) dendritic morphology of embryonic neurons in vitro (Jaworski et al., 2005) and mature RGCs upon injury to the optic nerve (Morquette et al., 2015), and (2) axon RGC growth/projection (Nie et al., 2010). Third, hRGCs expressed a battery of guidance molecules, and, as observed for rodents (de la Torre et al., 1997; Erskine and Herrera, 2007; Marcus et al., 1996; Stuermer and Bastmeyer, 2000), the response of their growth cones to those molecules was influenced by the activity of the mTOR pathway, suggesting that it supports the growth and guidance of hRGC axons. Furthermore, the mTOR pathway, besides involving guidance molecules, may recruit intrinsic factors such as KLF4, KLF6 and SOX11 to regulate axon growth. Lastly, axons of hRGCs, particularly those expressing the αRGC subtype marker SMI32, like those in rodents (Duan et al., 2015; Leibinger et al., 2012; Park et al., 2008), are capable of regeneration, the efficiency of which is regulated by the mTOR pathway, thus corroborating that mTOR activity-mediated axon regeneration is evolutionarily conserved from worms to humans (Byrne et al., 2014; Liu et al., 2010; Nawabi et al., 2012; Park et al., 2008).

Our observations suggest that, besides the mTOR pathway, other intrinsic factors and their interactions underlying axon regeneration are conserved in hRGCs. A variety of approaches that included constitutive expression of the effector of the JAK-STAT3 pathway, STAT3 (Pernet et al., 2013), conditional knockout of the JAK-STAT3 pathway inhibitor SOCS3, and the direct recruitment of the GP130 receptor by hIL6 (Leibinger et al., 2016) in rodent RGCs have demonstrated the essential role of the pathway in RGCs axon regeneration and growth following optic nerve injury. Evidence has emerged that the mTOR and JAK-STAT3 pathways may act in concert to promote RGC axon growth. For example, combined activation of both pathways by co-deletion with PTEN and SOCS3 (Sun et al., 2011) or continuous expression of hIL6 in combination with PTEN deletion causes robust axon regeneration (Fischer, 2017; Leibinger et al., 2016). That the JAK-STAT3 pathway is recruited in hRGCs axon regeneration and may act in concert with the mTOR pathway is suggested by hIL6-mediated axon regeneration following axotomy and the additive effect on the process when the mTOR pathway was co-activated. Though the evidence that cytokines increase the levels of p-S6 and that rapamycin inhibits the JAK-STAT pathway-mediated neurite and axon growth (Leibinger et al., 2016) suggests direct interactions between the two pathways, our observation suggests that the mTOR pathway may involve KLF4, a negative regulator of axon growth (Moore et al., 2009), for the ancillary recruitment of the JAK-STAT3 pathway. For example, we observed a significant decrease in KLF4 expression upon activation of the mTOR pathway. As KLF4 is known to inhibit the transcriptional function of STAT3 by binding directly to it (Qin et al., 2013), a decrease in its expression upon the mTOR activation may disinhibit STAT3, thus facilitating STAT3-mediated axon growth.

The mTOR-KLF4-JAK-STAT3 axis may be involved in the development of the disease phenotype in glaucoma. For example, the axis is dysregulated in hRGCs generated from the SIX6 risk allele-carrying primary open angle glaucoma (POAG) patient-specific induced pluripotent cells (Teotia et al., 2017b). SIX6, one of the eye field genes, regulates the generation of retinal cell types by maintaining retinal progenitors (Heavner and Pevny, 2012; Teotia et al., 2017b; Zuber et al., 2003). Therefore, its absence leads to hypoplastic retina in mouse due to the depletion of retinal progenitors (Li et al., 2002; Teotia et al., 2017b). POAG patients with this SIX6 risk allele variant (rs33912345; C>A; His141Asn) have reduced retinal nerve fiber layer (RNFL) thickness (Carnes et al., 2014; Iglesias et al., 2014). SIX6 risk allele RGCs displayed short and simple neurites and reduced expression of guidance molecules compared with controls. The differentially expressed genes mapping on the mTOR and JAK-STAT3 pathways were repressed in SIX6 risk allele hRGCs, compared with controls, suggesting that both pathways were inhibited in the disease condition. In contrast, expression of KLF4 was significantly higher in SIX6 risk allele RGCs versus controls. Together, these observations suggest that, given the observations that both the mTOR and JAK-STAT3 pathways play important roles in neurite growth and KLF4 inhibits it (Fischer, 2017; Moore et al., 2009; Park et al., 2008), the dysregulated axis as observed in SIX6 risk allele RGCs, if maintained in adulthood, may make them susceptible to degeneration. Clinical targeting of the mTOR pathway to rescue RGC degeneration may involve pharmacological activation of the pathway. Recently, a small molecule, NV-5138, has been shown to activate mTORC1 both in vivo and in vitro (Kato et al., 2019; Sengupta et al., 2019). Alternatively, to address the concern that pharmacological activation of the mTOR pathway may affect the function of other cell types because of its ubiquitous presence, RGCs could be targeted for silencing the TSC2 gene by adeno-associated virus sera 2 (AAV2) transduction, which is RGC specific in the adult retina (Hanlon et al., 2017; Harvey et al., 2009). In summary, with the caveat that hRGCs studied here do not reflect the age of the onset of glaucomatous degeneration, our study demonstrates that the mTOR pathway is an evolutionarily conserved modulator of hRGC development and regenerative ability, and thus emerges as a valid target for understanding glaucomatous degeneration and potential therapeutic regeneration.

MATERIALS AND METHODS

Experimental animals and use

The use of animals and experimental protocols were approved by the Institutional Animal Care and Use Committee, at the University of Nebraska Medical Center (UNMC) and conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. Timed-pregnant Sprague Dawley rats (Charles River Laboratories) were used for harvesting retinal cells from E14 and E18 embryos. Rats were euthanized by CO2 exposure followed by decapitation with sterile surgical scissors to ensure death.

hiPSC culture maintenance and expansion

hiPSCs generated from normal adult human peripheral blood mononuclear cells using a non-integrating approach as previously described (Teotia et al., 2017b) were maintained in mTeSR1 medium (Stem Cell Technologies) on Matrigel-coated 6-well plates. Cells were passaged at 70-80% confluency as small clumps using cell dissociation reagent (Stem Cell Technologies) and maintained in a 37°C/5% CO2 incubator. Cell passaging was performed at a 1:3 to 1:4 split ratio every 5 days.

Differentiation of E18 RPCs and hiPSCs into RGCs

Differentiation of hiPSCs along the retinal lineage was performed using a previously published protocol (Lamba et al., 2010). The directed differentiation of both E18 and hiPSCs-derived neural rosettes (NRs) into functional RGCs was performed using chemically defined medium following our established protocol (Teotia et al., 2017a). Briefly, NRs were manually picked and plated onto Matrigel-coated dishes (Corning), and RGC differentiation was initiated by treating cells for 2 days with Shh (250 ng/ml), FGF8 (100 ng/ml) and DAPT (3 μM). RGC differentiation was facilitated by treatment with follistatin (100 ng/ml), Shh (250 ng/ml) and DAPT (3 μM) for 3 days. Finally, RGC maturation and survival were promoted by supplementing the medium with BDNF (100 ng/ml), forskolin (10 μM), NT4 (5 ng/ml), CNTF (10 ng/ml), cAMP (400 μM), Y27632 (10 μM) and DAPT (3 μM) for the next 10 days. The medium was changed every 2-3 days. All reagents were purchased from R&D Systems.

Plasmid constructs and virus preparation

The TSC2-shRNA:GFP and Control-shRNA:GFP constructs (Di Nardo et al., 2009) were generous gifts from Prof. Mustafa Sahin (Boston Children's Hospital, USA). Lentivirus transduction was carried out as previously described (Xia et al., 2018). Recombination lentiviral particles were generated through transient transfection of T293 cells, using the ABM lentivirus packaging system (Applied Biological Materials). Viral particles were concentrated using a BioVision PEG lentivirus precipitation kit (BioVision). Viral particles were collected 48 h and 72 h after transfection and filtered through a 0.45 μm membrane. Virus titers were determined using the ABM lentivirus titration kit. Twelve hours after transduction, the virus-containing medium was replaced by fresh medium. Transduction efficiency was determined 24 h post-transduction by direct observation of GFP+ cells. GFP+ cells per total DAPI+ cells were used for quantitative analyses of transduction efficiency in five visual fields per coverslip.

Baculoviral hyper-IL6 expression

Recombinant baculoviruses were produced using the ViraPower BacMam Expression System (Thermo Fisher) according to manufacturer's protocols. In brief, recombinant bacmid DNA was purified and transfected into adherent Sf9 cells (Thermo Fisher) using Cellfectin reagent to generate P1 recombinant baculovirus stock. Baculoviruses were amplified by inoculation of 50 ml Sf9 suspension cultures (106 cells/ml) in Sf-900 III SFM Medium supplemented with 12.5 U/ml penicillin/streptomycin (Biochrom) in 125 ml polycarbonate Erlenmeyer flasks with vent cap (Corning) with 1 ml virus stock solution and incubation at 27°C and 130 rpm for 2-3 days. Amplified viruses were purified and concentrated by ultracentrifugation of 27 ml virus-containing supernatant underlaid with 2.7 ml sucrose solution (25% sucrose with 5 mM NaCl and 10 mM EDTA in H2O) in OptiSeal polypropylene tubes (Beckmann Coulter) at 80,000 g and 4°C for 80 min. Viral pellets were re-suspended in 0.5 ml PBS and passed through 0.22 μm low protein-binding sterile syringe filters (Merck Millipore). Baculovirus preparations were pre-tested on HEK293 cells (seeded at ∼3-5×104 cells per well in 96-well plates) by adding 1 μl virus per well overnight. Transduction efficiencies of ≥90% were regarded appropriate for further use. Otherwise, virus stock was subjected to further amplification cycles.

shRNA lentiviral-mediated gene silencing

hRGCs were infected with TSC2-shRNA-GFP/Control-shRNA:GFP lentivirus at 1 day in vitro (DIV) of RGC differentiation in the presence of polybrene at 0.6 μg/ml. Twelve hours after infection the virus-containing medium was replaced by fresh RGC differentiation medium. GL3: hRGCs were exposed to rapamycin (Sigma) at a final concentration of 2.5 μM to inhibit the mTOR activity. After infection, hRGCs were kept in culture for an additional 14 days. The perturbation experiments were carried out three times in triplicate. For JAK-STAT3 pathway perturbation, hRGCs were transduced at 1 DIV with hIL6:GFP-baculoviruses or GFP (empty vector)-baculoviruses as described earlier (Fischer, 2017). hIL6 hRGCs were exposed to AG490 (Calbiochem) at a final concentration of 10 μM to inhibit JAK-STAT3 activity.

Culturing of hRGCs in microfluidic devices

Polydimethylsiloxane microfluidic devices with 450 μm microgrooves (SND 450, Xona Microfluidics) were assembled and prepared as per the manufacturer's instruction. Briefly, cleaned, sterilized, and dry devices were reversibly attached to poly-D-lysine (PDL, Sigma)-coated cover glass by applying gentle force to seal them (Corning, 50×24 mm) (one device per cover glass) for axonal outgrowth and regeneration studies. The cover glasses were coated overnight with 1 mg/ml poly-D-lysine (Sigma-Aldrich). Once assembled, a solution of 1% Matrigel (Corning) in DMEM/F-12 medium (Invitrogen) was added to the four reservoirs/well (both side soma and axonal compartment) of the device. Devices were coated with Matrigel for at least 1 h at room temperature before cell seeding. After accutase dissociation at 5 DIV, hRGCs were re-suspended at 100,000 cells/ml in RGC maturation and survival media and loaded into the micro-channel in a 2 μl droplet. Cells were allowed to attach for at least 30 min, after which medium was added into the adjacent wells. The axonal compartment was filled with similar medium to facilitate axonal growth. Volumes in the wells were adapted to ensure flow across compartments to gradually provide medium and to establish a flow from the soma (200 μl per well) to the axonal (150 μl per well) compartment. Media in the devices was changed every 2 days.

Chemical axotomy

Axotomy was performed between 10 and 12 DIV by first removing media from the axonal compartment and adding 50 μl RGC medium with 0.5% saponin (Sigma) for 3 min. To prevent the flow of the detergent into the soma compartment, a hydrostatic pressure was maintained by volume difference between soma (200 μl/well) and axonal (50 μl/well) compartments. At the end of a 3 min period, followed by two PBS washes, the axonal compartment was re-coated with 1% Matrigel for 30 min at 37°C. After Matrigel coating, media was returned immediately to the axonal compartment for the duration of the culture time. For the axotomy and regeneration experiment, hRGCs post-axotomy were cultured for an additional 5 DIV followed by retrograde labeling to identify regenerated axons. hRGC media post-axotomy was supplemented with rapamycin (Sigma; 2.5 μM), AG490 (Calbiochem; 10 μM) or rapamycin+AG490 to check the effect of perturbation of the mTOR, JAK-STAT3, and mTOR+JAK-STAT3 pathways, respectively.

Retrograde labeling

Retrograde labeling was performed using 1% cholera toxin subunit B Alexa Fluor 594 conjugate (Thermo Fisher) dissolved in RGC media and added to the axonal compartment (100 μl per well) of the microfluidic device and incubated overnight at 37°C. After overnight incubation, the axonal compartment media was removed, rinsed, and replaced using fresh RGC culture media before imaging.

Western blot analysis

Protein samples (10-50 μg), extracted from hRGCs (Control, TSC2 and Rapamycin groups in triplicate) at the end of differentiation using RIPA buffer (Thermo Fisher), were denatured and separated by sodium dodecyl sulfate-polyacrylamide gel (12%) electrophoresis, and transferred onto a 0.45 µm PVDF-Plus Transfer Membrane (GE Water&Process Technologies). Membranes were incubated for 2 h at room temperature in blocking solution [5% non-fat milk powder dissolved in TBST buffer (0.15 M NaCl, 20 mM Tris, 0.05% Tween-20)], at room temperature for 2 h, followed by overnight incubation at 4°C with primary antibodies at recommended dilutions (Table S1). Membranes were washed and incubated with anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) for 1 h at room temperature and visualized with an enhanced chemiluminescence reagent (ECL Plus Western Blotting Detection System, Amersham) using Syngene gel documentation system (Fredrick). Immunoreactive bands corresponding to S6, p-S6 and GAPDH (loading control) were scanned using Gene Tools image analysis software (Syngene). All western blots shown are representative of at least three independent experiments.

Immunocytochemistry, image acquisition, and data analysis

For immunocytochemical analysis, cells were fixed in 4% paraformaldehyde for 15 min. After two rinses with PBS, fixed cells were exposed to 5% normal goat/donkey serum in PBS for 30 min at room temperature and permeabilized with Triton X-100 (0.4% or 0.2% for nuclear or cytoplasmic staining, respectively), followed by overnight incubation with primary antibody at 4°C. The next day, cells were treated with fluorescence (Cy3/FITC)-tagged secondary antibodies (Life Technologies) diluted in a 5% donkey serum and 0.2%/0.4% Triton X-100 solution for 2 h at room temperature, followed by three washes with PBS. Samples were mounted using VectaShield (Vector Laboratories) and fluorescent images were acquired with Zeiss ApoTome Imager M2 upright microscope (Axiovert 200M) and Axiovision 4.8 software (Carl Zeiss). The percentage of cells expressing specific markers was determined by counting immunopositive cells co-expressing GFP per total GFP-positive cells in five visual fields per coverslip. For each experimental condition, three biological replicates were used to calculate means and standard deviation. A list of antibodies and working dilutions is provided in Table S1. For growth cone analyses, Alexa Fluor 594-phalloidin staining (Cytoskeleton) for F-actin was carried out by incubation at 1:100 dilution in PBS containing 5% normal goat serum for 30 min after fixation and permeabilization, as per manufacturer's instruction. Neurite complexity and length quantification was performed using Fiji software (ImageJ, National Institutes of Health) (Schmidt and Kofuji, 2009). The percentage of GFP+CY3+ axons was calculated by counting the numbers of both GFP+ and CY3+ axons out of total numbers of CY3+ axons that crossed the microgroove and were present in an axonal compartment at the time of imaging.

Time-lapse imaging of growth cone dynamics

hRGCs were plated on glass-bottom Petri dishes/microfluidics device for time-lapse imaging and images were acquired on an inverted confocal laser-scanning microscope (Zeiss 710 confocal laser scanning microscope, combined with Zeiss Zen Blue software) using an EC Plan-NEOFLUAR 60× objective lens with additional 1.5× magnification. Following 30 min of imaging, purified recombinant netrin-1 at 50 ng/ml concentration was bath-applied, and the same growth cones were imaged for an additional 30 min. For DCC function-blocking experiments, either anti-DCC (5 μg/ml, BD Biosciences) or the control antibody (control mouse IgG; 5 μg/ml, Millipore) was added to hRGC medium to achieve a final concentration of 10 μg/ml before and during the experiment. To check the response of Netrin-1 under the influence of the mTOR pathway, 50 ng/ml Netrin-1 was added to the hRGC medium in the axonal compartment in a microfluidics device. After 3 days, cells were stained with Alexa Fluor 594-phalloidin and imaged with a confocal microscope as above.

Quantitative polymerase chain reaction analysis

Quantitative polymerase chain reaction (Q-PCR) analysis was carried out as previously described (Teotia et al., 2017a). Total RNA from cells was extracted using Mini-RNeasy kit (Qiagen) according to the manufacturer's instructions. Five μg of total RNA per sample was used for reverse transcription into cDNA, using Superscript III RT kit, following the manufacturer's instructions. Q-PCR was performed using Quantifast SYBR Green Master Mix (Qiagen) on Rotor Gene 6000 (Corbett Robotics). All qPCR results represent each sample measured in triplicate. No-template blanks were used for negative controls. Amplification curves and gene expressions were normalized to the housekeeping gene GAPDH. The primer sequences used in this study are listed in Table S2.

Electrophysiological recordings

Electrophysiological analysis was performed as described previously (Teotia et al., 2017b) using an upright fixed-stage microscope (Olympus BX51WI or Scientifica SliceScope Pro 6000) equipped with a 40× (Olympus) or 20× (Scientifica) water immersion objective lens. Cells were superfused with Ames' Medium (US Biologicals) at room temperature. Recording micropipettes (tip resistances 8-12 MΩ) were filled with an internal solution composed of (in mM) 120 potassium gluconate, 5 NaCl, 10 KCl, 2 EGTA, 10 HEPES, 5 ATP-Mg, 0.5 GTP-Na2, 5 phosphocreatine-Na2. The pH of the pipette solution was adjusted to 7.4 with KOH, and the osmolality was measured with a vapor pressure osmometer (Wescor) and adjusted to 270-275 mOsm. Reported voltages were corrected for liquid junction potential (10 mV). Electrophysiological recordings were obtained with Multiclamp 700A and 700B amplifiers, a Digidata 1500B digitizer, and pClamp 10.4 software (Molecular Devices). Na+ and K+ currents were evoked by voltage steps from −70 to +40 mV in 10 mV increments and action potentials evoked with a series of depolarizing current injections in current clamp (+10 to +70 pA) while passive membrane properties were measured with hyperpolarizing current injections (−10 to −40 pA). Resting potential was measured without any current injection, and a hyperpolarizing DC injection was used to hold the resting membrane potential at approximately −75 mV for measurements of evoked spiking behavior.

Calcium imaging

Calcium imaging in hRGCControl, hRGCTSC2 and hRGCRapamycin to investigate spontaneous Ca2+ transients was performed as described previously (Teotia et al., 2017b). Briefly, cells at the end of differentiation from all the groups were loaded with 3 μM Fluo-4-AM dye (Life Technologies) in HEPES-buffered physiological saline solution, supplemented with 0.04% Pluronic-F27 (Life Technologies) for 60 min at room temperature, followed by three to five washes with HEPES-buffered physiological saline solution. For each group, three Ca2+-imaging sessions (each session contains three fields of view) were collected from independent samples. All imaging was carried out using an inverted confocal laser-scanning microscope (Zeiss 710 confocal laser scanning microscope, combined with Zeiss Zen Blue software) using an EC Plan-NEOFLUAR 10×/0.30 M27 objective lens (Carl Zeiss). Images were taken every 3 s, with 300 frames recorded per field. For representation and analysis, a total of three independent samples were tested per group and up to four 600 s videos of spontaneous calcium transients analyzed. Using Zen Blue software, a region of interest (ROI) was manually selected and mean pixel intensity of each ROI followed over time, generating time trace data for each ROI. The mean amplitude of spontaneous calcium transients was presented as relative fluorescence changes of averaged ROI [ΔF/F0=(F-F0)/F0; signal to baseline ratio of fluorescence]. The number of spontaneous calcium transients per minute was manually calculated.

Flow cytometry

Cells dissociated to a single cell suspension were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.4% Triton X-100 for additional 15 min at room temperature. Cells were further incubated for 1 h at 4°C with BRN3A antibody followed by two PBS washes. Cy3-tagged secondary antibody was used to allow for data acquisition and analysis. For Live/Dead assay, cells were measured using the LIVE/DEAD Fixable Dead Cell Stain Kit (Thermo Fisher Scientific). This method uses blue fluorescent reactive dye to stain the cells with damaged membranes as per manufacturer's protocol. Briefly, cells were pelleted, washed with 1× PBS, and stained with 1 µl of fluorescent reactive dye from the LIVE/DEAD Stain Kit. Cells were incubated on ice for 30 min in the dark. Data was captured using the LSRII flow cytometer system (Beckman Coulter). At least 10,000 events were recorded for each sample. Data analysis was performed BD FACSDiva software version 6.1.2.

Statistical analysis

Values are expressed as mean±s.e.m. Data were analyzed and plotted using GraphPad Prism (GraphPad). Statistical significance was determined by either a paired Student's t-test (two-tailed) or by one-way analysis of variance (ANOVA) for multiple group comparison. P-values of <0.05 were considered significant. Statistical analysis was performed when each group had at least three replicate samples from two independent experiments.

Acknowledgements

Thanks are due to Dr Mustafa Sahin for TSC2 lentivirus constructs and Helen Erickson for technical assistance.

Footnotes

  • Competing interests

    The authors declare no competing or financial interests.

  • Author contributions

    Conceptualization: I.A.; Methodology: P.T., M.J.V.H., I.A.; Software: P.T.; Validation: D.F., I.A.; Formal analysis: P.T., M.J.V.H., D.F., I.A.; Investigation: P.T., M.J.V.H., D.F.; Resources: D.F.; Data curation: P.T., I.A.; Writing - original draft: P.T., I.A.; Visualization: I.A.; Supervision: I.A.; Project administration: I.A.; Funding acquisition: I.A.

  • Funding

    This research was supported by the National Eye Institute (2R01EY022051) and Nebraska Department of Health and Human Services (LB606). Deposited in PMC for release after 12 months.

  • Supplementary information

    Supplementary information available online at http://dev.biologists.org/lookup/doi/10.1242/dev.178012.supplemental

  • Received March 12, 2019.
  • Accepted May 15, 2019.

References

  1. ↵
    1. Almasieh, M.,
    2. Wilson, A. M.,
    3. Morquette, B.,
    4. Cueva Vargas, J. L. and
    5. Di Polo, A.
    (2012). The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 31, 152-181. doi:10.1016/j.preteyeres.2011.11.002
    OpenUrlCrossRefPubMed
  2. ↵
    1. Byrne, A. B.,
    2. Walradt, T.,
    3. Gardner, K. E.,
    4. Hubbert, A.,
    5. Reinke, V. and
    6. Hammarlund, M.
    (2014). Insulin/IGF1 signaling inhibits age-dependent axon regeneration. Neuron 81, 561-573. doi:10.1016/j.neuron.2013.11.019
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Carnes, M. U.,
    2. Liu, Y. P.,
    3. Allingham, R. R.,
    4. Whigham, B. T.,
    5. Havens, S.,
    6. Garrett, M. E.,
    7. Qiao, C.
    , Neighborhood Consortium Investigators, Katsanis, N., Wiggs, J. L. et al. (2014). Discovery and functional annotation of SIX6 variants in primary open-angle glaucoma. PLoS Genet. 10, e1004372. doi:10.1371/journal.pgen.1004372
    OpenUrlCrossRefPubMed
  4. ↵
    1. Choi, Y.-J.,
    2. Di Nardo, A.,
    3. Kramvis, I.,
    4. Meikle, L.,
    5. Kwiatkowski, D. J.,
    6. Sahin, M. and
    7. He, X.
    (2008). Tuberous sclerosis complex proteins control axon formation. Genes Dev. 22, 2485-2495. doi:10.1101/gad.1685008
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Choi, J. H.,
    2. Jo, H. S.,
    3. Lim, S.,
    4. Kim, H. T.,
    5. Lee, K. W.,
    6. Moon, K. H.,
    7. Ha, T.,
    8. Kwak, S. S.,
    9. Kim, Y.,
    10. Lee, E. J. et al.
    (2019). mTORC1 accelerates retinal development via the immunoproteasome. Nat Commun. 9, 2502. doi:10.1038/s41467-018-04774-9
    OpenUrlCrossRef
  6. ↵
    1. Costa-Mattioli, M. and
    2. Monteggia, L. M.
    (2013). mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat. Neurosci. 16, 1537-1543. doi:10.1038/nn.3546
    OpenUrlCrossRefPubMed
  7. ↵
    1. Curcio, M. and
    2. Bradke, F.
    (2018). Axon regeneration in the central nervous system: facing the challenges from the inside. Annu. Rev. Cell Dev. Biol. 34, 495-521. doi:10.1146/annurev-cellbio-100617-062508
    OpenUrlCrossRef
  8. ↵
    1. de la Torre, J. R.,
    2. Höpker, V. H.,
    3. Ming, G.-L.,
    4. Poo, M.-M.,
    5. Tessier-Lavigne, M.,
    6. Hemmati-Brivanlou, A. and
    7. Holt, C. E.
    (1997). Turning of retinal growth cones in a netrin-1 gradient mediated by the netrin receptor DCC. Neuron 19, 1211-1224. doi:10.1016/S0896-6273(00)80413-4
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Di Nardo, A.,
    2. Kramvis, I.,
    3. Cho, N.,
    4. Sadowski, A.,
    5. Meikle, L.,
    6. Kwiatkowski, D. J. and
    7. Sahin, M.
    (2009). Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J. Neurosci. 29, 5926-5937. doi:10.1523/JNEUROSCI.0778-09.2009
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Du, K.,
    2. Zheng, S.,
    3. Zhang, Q.,
    4. Li, S.,
    5. Gao, X.,
    6. Wang, J.,
    7. Jiang, L. and
    8. Liu, K.
    (2015). Pten deletion promotes regrowth of corticospinal tract axons 1 year after spinal cord injury. J. Neurosci. 35, 9754-9763. doi:10.1523/JNEUROSCI.3637-14.2015
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Duan, X.,
    2. Qiao, M.,
    3. Bei, F.,
    4. Kim, I.-J.,
    5. He, Z. and
    6. Sanes, J. R.
    (2015). Subtype-specific regeneration of retinal ganglion cells following axotomy: effects of osteopontin and mTOR signaling. Neuron 85, 1244-1256. doi:10.1016/j.neuron.2015.02.017
    OpenUrlCrossRefPubMed
  12. ↵
    1. Erskine, L. and
    2. Herrera, E.
    (2007). The retinal ganglion cell axon's journey: insights into molecular mechanisms of axon guidance. Dev. Biol. 308, 1-14. doi:10.1016/j.ydbio.2007.05.013
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Erskine, L.,
    2. Williams, S. E.,
    3. Brose, K.,
    4. Kidd, T.,
    5. Rachel, R. A.,
    6. Goodman, C. S.,
    7. Tessier-Lavigne, M. and
    8. Mason, C. A.
    (2000). Retinal ganglion cell axon guidance in the mouse optic chiasm: expression and function of robos and slits. J. Neurosci. 20, 4975-4982. doi:10.1523/JNEUROSCI.20-13-04975.2000
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Fischer, D.
    (2017). Hyper-IL-6: a potent and efficacious stimulator of RGC regeneration. Eye (Lond) 31, 173-178. doi:10.1038/eye.2016.234
    OpenUrlCrossRefPubMed
  15. ↵
    1. Garza-Lombó, C. and
    2. Gonsebatt, M. E.
    (2016). Mammalian target of rapamycin: its role in early neural development and in adult and aged brain function. Front. Cell Neurosci. 10, 157. doi:10.3389/fncel.2016.00157
    OpenUrlCrossRef
  16. ↵
    1. Hanlon, K. S.,
    2. Chadderton, N.,
    3. Palfi, A.,
    4. Blanco Fernandez, A.,
    5. Humphries, P.,
    6. Kenna, P. F.,
    7. Millington-Ward, S. and
    8. Farrar, G. J.
    (2017). A novel retinal ganglion cell promoter for utility in AAV vectors. Front. Neurosci. 11, 521. doi:10.3389/fnins.2017.00521
    OpenUrlCrossRef
  17. ↵
    1. Harvey, A. R.,
    2. Hellström, M. and
    3. Rodger, J.
    (2009). Gene therapy and transplantation in the retinofugal pathway. Prog. Brain Res. 175, 151-161. doi:10.1016/S0079-6123(09)17510-6
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Heavner, W. and
    2. Pevny, L.
    (2012). Eye development and retinogenesis. Cold Spring Harb. Perspect. Biol. 4, a008391. doi:10.1101/cshperspect.a008391
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Hilton, B. J. and
    2. Bradke, F.
    (2017). Can injured adult CNS axons regenerate by recapitulating development? Development 144, 3417-3429. doi:10.1242/dev.148312
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Hindges, R.,
    2. McLaughlin, T.,
    3. Genoud, N.,
    4. Henkemeyer, M. and
    5. O'Leary, D. D. M.
    (2002). EphB forward signaling controls directional branch extension and arborization required for dorsal-ventral retinotopic mapping. Neuron 35, 475-487. doi:10.1016/S0896-6273(02)00799-7
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Hoshino, A.,
    2. Ratnapriya, R.,
    3. Brooks, M. J.,
    4. Chaitankar, V.,
    5. Wilken, M. S.,
    6. Zhang, C.,
    7. Starostik, M. R.,
    8. Gieser, L.,
    9. La Torre, A.,
    10. Nishio, M. et al.
    (2017). Molecular anatomy of the developing human retina. Dev. Cell 43, 763-779.e764. doi:10.1016/j.devcel.2017.10.029
    OpenUrlCrossRefPubMed
  22. ↵
    1. Huang, J.,
    2. Dibble, C. C.,
    3. Matsuzaki, M. and
    4. Manning, B. D.
    (2008). The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 28, 4104-4115. doi:10.1128/MCB.00289-08
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Iglesias, A. I.,
    2. Springelkamp, H.,
    3. van der Linde, H.,
    4. Severijnen, L.-A.,
    5. Amin, N.,
    6. Oostra, B.,
    7. Kockx, C. E. M.,
    8. van den Hout, M. C. G. N.,
    9. van Ijcken, W. F. J.,
    10. Hofman, A. et al.
    (2014). Exome sequencing and functional analyses suggest that SIX6 is a gene involved in an altered proliferation-differentiation balance early in life and optic nerve degeneration at old age. Hum. Mol. Genet. 23, 1320-1332. doi:10.1093/hmg/ddt522
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Jaworski, J.,
    2. Spangler, S.,
    3. Seeburg, D. P.,
    4. Hoogenraad, C. C. and
    5. Sheng, M.
    (2005). Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 25, 11300-11312. doi:10.1523/JNEUROSCI.2270-05.2005
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Kato, T.,
    2. Pothula, S.,
    3. Liu, R.-J.,
    4. Duman, C. H.,
    5. Terwilliger, R.,
    6. Vlasuk, G. P.,
    7. Saiah, E.,
    8. Hahm, S. and
    9. Duman, R. S.
    (2019). Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J. Clin. Invest. 130, 2542-2554. doi:10.1172/JCI126859
    OpenUrlCrossRef
  26. ↵
    1. Krieger, B.,
    2. Qiao, M.,
    3. Rousso, D. L.,
    4. Sanes, J. R. and
    5. Meister, M.
    (2017). Four alpha ganglion cell types in mouse retina: function, structure, and molecular signatures. PLoS ONE 12, e0180091. doi:10.1371/journal.pone.0180091
    OpenUrlCrossRefPubMed
  27. ↵
    1. Kruger, K.,
    2. Tam, A. S.,
    3. Lu, C. and
    4. Sretavan, D. W.
    (1998). Retinal ganglion cell axon progression from the optic chiasm to initiate optic tract development requires cell autonomous function of GAP-43. J. Neurosci. 18, 5692-5705. doi:10.1523/JNEUROSCI.18-15-05692.1998
    OpenUrlAbstract/FREE Full Text
    1. Kurimoto, T.,
    2. Yin, Y.,
    3. Habboub, G.,
    4. Gilbert, H.-Y.,
    5. Li, Y.,
    6. Nakao, S.,
    7. Hafezi-Moghadam, A. and
    8. Benowitz, L. I.
    (2013). Neutrophils express oncomodulin and promote optic nerve regeneration. J. Neurosci. 33, 14816-14824. doi:10.1523/JNEUROSCI.5511-12.2013
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Lamba, D. A.,
    2. McUsic, A.,
    3. Hirata, R. K.,
    4. Wang, P.-R.,
    5. Russell, D. and
    6. Reh, T. A.
    (2010). Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS ONE 5, e8763. doi:10.1371/journal.pone.0008763
    OpenUrlCrossRefPubMed
  30. ↵
    1. Lee, D. Y.
    (2015). Roles of mTOR signaling in brain development. Exp. Neurobiol. 24, 177-185. doi:10.5607/en.2015.24.3.177
    OpenUrlCrossRefPubMed
  31. ↵
    1. Leibinger, M.,
    2. Andreadaki, A. and
    3. Fischer, D.
    (2012). Role of mTOR in neuroprotection and axon regeneration after inflammatory stimulation. Neurobiol. Dis. 46, 314-324. doi:10.1016/j.nbd.2012.01.004
    OpenUrlCrossRefPubMed
  32. ↵
    1. Leibinger, M.,
    2. Andreadaki, A.,
    3. Gobrecht, P.,
    4. Levin, E.,
    5. Diekmann, H. and
    6. Fischer, D.
    (2016). Boosting central nervous system axon regeneration by circumventing limitations of natural cytokine signaling. Mol. Ther. 24, 1712-1725. doi:10.1038/mt.2016.102
    OpenUrlCrossRefPubMed
  33. ↵
    1. Li, X.,
    2. Perissi, V.,
    3. Liu, F.,
    4. Rose, D. W. and
    5. Rosenfeld, M. G.
    (2002). Tissue-specific regulation of retinal and pituitary precursor cell proliferation. Science 297, 1180-1183. doi:10.1126/science.1073263
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Li, Y.,
    2. Struebing, F. L.,
    3. Wang, J.,
    4. King, R. and
    5. Geisert, E. E.
    (2018). Different effect of Sox11 in retinal ganglion cells survival and axon regeneration. Front. Genet. 9, 633. doi:10.3389/fgene.2018.00633
    OpenUrlCrossRef
  35. ↵
    1. Lin, B.,
    2. Wang, S. W. and
    3. Masland, R. H.
    (2004). Retinal ganglion cell type, size, and spacing can be specified independent of homotypic dendritic contacts. Neuron 43, 475-485. doi:10.1016/j.neuron.2004.08.002
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Liu, K.,
    2. Lu, Y.,
    3. Lee, J. K.,
    4. Samara, R.,
    5. Willenberg, R.,
    6. Sears-Kraxberger, I.,
    7. Tedeschi, A.,
    8. Park, K. K.,
    9. Jin, D.,
    10. Cai, B. et al.
    (2010). PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat. Neurosci. 13, 1075-1081. doi:10.1038/nn.2603
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Liu, K.,
    2. Tedeschi, A.,
    3. Park, K. K. and
    4. He, Z.
    (2011). Neuronal intrinsic mechanisms of axon regeneration. Annu. Rev. Neurosci. 34, 131-152. doi:10.1146/annurev-neuro-061010-113723
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Maiese, K.,
    2. Chong, Z. Z.,
    3. Shang, Y. C. and
    4. Wang, S.
    (2013). mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol. Med. 19, 51-60. doi:10.1016/j.molmed.2012.11.001
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Marcus, R. C.,
    2. Gale, N. W.,
    3. Morrison, M. E.,
    4. Mason, C. A. and
    5. Yancopoulos, G. D.
    (1996). Eph family receptors and their ligands distribute in opposing gradients in the developing mouse retina. Dev. Biol. 180, 786-789. doi:10.1006/dbio.1996.0347
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Moore, D. L. and
    2. Goldberg, J. L.
    (2011). Multiple transcription factor families regulate axon growth and regeneration. Dev. Neurobiol. 71, 1186-1211. doi:10.1002/dneu.20934
    OpenUrlCrossRefPubMed
  41. ↵
    1. Moore, D. L.,
    2. Blackmore, M. G.,
    3. Hu, Y.,
    4. Kaestner, K. H.,
    5. Bixby, J. L.,
    6. Lemmon, V. P. and
    7. Goldberg, J. L.
    (2009). KLF family members regulate intrinsic axon regeneration ability. Science 326, 298-301. doi:10.1126/science.1175737
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Morgan-Warren, P. J.,
    2. Berry, M.,
    3. Ahmed, Z.,
    4. Scott, R. A. H. and
    5. Logan, A.
    (2013). Exploiting mTOR signaling: a novel translatable treatment strategy for traumatic optic neuropathy? Invest. Ophthalmol. Vis. Sci. 54, 6903-6916. doi:10.1167/iovs.13-12803
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Morquette, B.,
    2. Morquette, P.,
    3. Agostinone, J.,
    4. Feinstein, E.,
    5. McKinney, R. A.,
    6. Kolta, A. and
    7. Di Polo, A.
    (2015). REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury. Cell Death Differ. 22, 612-625. doi:10.1038/cdd.2014.149
    OpenUrlCrossRefPubMed
  44. ↵
    1. Nawabi, H.,
    2. Zukor, K. and
    3. He, Z.
    (2012). No simpler than mammals: axon and dendrite regeneration in Drosophila. Genes Dev. 26, 1509-1514. doi:10.1101/gad.198150.112
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Nie, D.,
    2. Di Nardo, A.,
    3. Han, J. M.,
    4. Baharanyi, H.,
    5. Kramvis, I.,
    6. Huynh, T. T.,
    7. Dabora, S.,
    8. Codeluppi, S.,
    9. Pandolfi, P. P.,
    10. Pasquale, E. B. et al.
    (2010). Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat. Neurosci. 13, 163-172. doi:10.1038/nn.2477
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Norsworthy, M. W.,
    2. Bei, F.,
    3. Kawaguchi, R.,
    4. Wang, Q.,
    5. Tran, N. M.,
    6. Li, Y.,
    7. Brommer, B.,
    8. Zhang, Y.,
    9. Wang, C.,
    10. Sanes, J. R. et al.
    (2017). Sox11 expression promotes regeneration of some retinal ganglion cell types but kills others. Neuron 94, 1112-1120.e1114. doi:10.1016/j.neuron.2017.05.035
    OpenUrlCrossRefPubMed
  47. ↵
    1. Oh, Y. M.,
    2. Mahar, M.,
    3. Ewan, E. E.,
    4. Leahy, K. M.,
    5. Zhao, G. and
    6. Cavalli, V.
    (2018). Epigenetic regulator UHRF1 inactivates REST and growth suppressor gene expression via DNA methylation to promote axon regeneration. Proc. Natl. Acad. Sci. USA 115, E12417-E12426. doi:10.1073/pnas.1812518115
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Park, K. K.,
    2. Liu, K.,
    3. Hu, Y.,
    4. Smith, P. D.,
    5. Wang, C.,
    6. Cai, B.,
    7. Xu, B.,
    8. Connolly, L.,
    9. Kramvis, I.,
    10. Sahin, M. et al.
    (2008). Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 322, 963-966. doi:10.1126/science.1161566
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Pernet, V.,
    2. Joly, S.,
    3. Jordi, N.,
    4. Dalkara, D.,
    5. Guzik-Kornacka, A.,
    6. Flannery, J. G. and
    7. Schwab, M. E.
    (2013). Misguidance and modulation of axonal regeneration by Stat3 and Rho/ROCK signaling in the transparent optic nerve. Cell Death Dis. 4, e734. doi:10.1038/cddis.2013.266
    OpenUrlCrossRefPubMed
  50. ↵
    1. Qin, S.,
    2. Zou, Y. and
    3. Zhang, C. L.
    (2013). Cross-talk between KLF4 and STAT3 regulates axon regeneration. Nat. Commun. 4, 2633. doi:10.1038/ncomms3633
    OpenUrlCrossRefPubMed
  51. ↵
    1. Sarbassov, D. D.,
    2. Ali, S. M. and
    3. Sabatini, D. M.
    (2005). Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603. doi:10.1016/j.ceb.2005.09.009
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Saxton, R. A. and
    2. Sabatini, D. M.
    (2017). mTOR signaling in growth, metabolism, and disease. Cell 168, 960-976. doi:10.1016/j.cell.2017.02.004
    OpenUrlCrossRefPubMed
  53. ↵
    1. Schmidt, T. M. and
    2. Kofuji, P.
    (2009). Functional and morphological differences among intrinsically photosensitive retinal ganglion cells. J. Neurosci. 29, 476-482. doi:10.1523/JNEUROSCI.4117-08.2009
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Sengupta, S.,
    2. Giaime, E.,
    3. Narayan, S.,
    4. Hahm, S.,
    5. Howell, J.,
    6. O'Neill, D.,
    7. Vlasuk, G. P. and
    8. Saiah, E.
    (2019). Discovery of NV-5138, the first selective Brain mTORC1 activator. Sci. Rep. 9, 4107. doi:10.1038/s41598-019-40693-5
    OpenUrlCrossRef
  55. ↵
    1. Sholl, D. A.
    (1953). Dendritic organization in the neurons of the visual and motor cortices of the cat. J. Anat. 87, 387-406.
    OpenUrlPubMedWeb of Science
  56. ↵
    1. Smith, P. D.,
    2. Sun, F.,
    3. Park, K. K.,
    4. Cai, B.,
    5. Wang, C.,
    6. Kuwako, K.,
    7. Martinez-Carrasco, I.,
    8. Connolly, L. and
    9. He, Z.
    (2009). SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron 64, 617-623. doi:10.1016/j.neuron.2009.11.021
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    1. Spitzer, N. C.,
    2. Root, C. M. and
    3. Borodinsky, L. N.
    (2004). Orchestrating neuronal differentiation: patterns of Ca2+ spikes specify transmitter choice. Trends Neurosci. 27, 415-421. doi:10.1016/j.tins.2004.05.003
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Stuermer, C. A. O. and
    2. Bastmeyer, M.
    (2000). The retinal axon's pathfinding to the optic disk. Prog. Neurobiol. 62, 197-214. doi:10.1016/S0301-0082(00)00012-5
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Sun, F.,
    2. Park, K. K.,
    3. Belin, S.,
    4. Wang, D.,
    5. Lu, T.,
    6. Chen, G.,
    7. Zhang, K.,
    8. Yeung, C.,
    9. Feng, G.,
    10. Yankner, B. A. et al.
    (2011). Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature 480, 372-375. doi:10.1038/nature10594
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. Swiech, L.,
    2. Perycz, M.,
    3. Malik, A. and
    4. Jaworski, J.
    (2008). Role of mTOR in physiology and pathology of the nervous system. Biochim. Biophys. Acta 1784, 116-132. doi:10.1016/j.bbapap.2007.08.015
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Tassew, N. G.,
    2. Charish, J.,
    3. Shabanzadeh, A. P.,
    4. Luga, V.,
    5. Harada, H.,
    6. Farhani, N.,
    7. D'Onofrio, P.,
    8. Choi, B.,
    9. Ellabban, A.,
    10. Nickerson, P. E. B. et al.
    (2017). Exosomes mediate mobilization of autocrine Wnt10b to promote axonal regeneration in the injured CNS. Cell Rep. 20, 99-111. doi:10.1016/j.celrep.2017.06.009
    OpenUrlCrossRef
  62. ↵
    1. Tee, A. R.,
    2. Sampson, J. R.,
    3. Pal, D. K. and
    4. Bateman, J. M.
    (2016). The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Semin. Cell Dev. Biol. 52, 12-20. doi:10.1016/j.semcdb.2016.01.040
    OpenUrlCrossRefPubMed
  63. ↵
    1. Teotia, P.,
    2. Chopra, D. A.,
    3. Dravid, S. M.,
    4. Van Hook, M. J.,
    5. Qiu, F.,
    6. Morrison, J.,
    7. Rizzino, A. and
    8. Ahmad, I.
    (2017a). Generation of functional human retinal ganglion cells with target specificity from pluripotent stem cells by chemically defined recapitulation of developmental mechanism. Stem Cells 35, 572-585. doi:10.1002/stem.2513
    OpenUrlCrossRef
  64. ↵
    1. Teotia, P.,
    2. Van Hook, M. J.,
    3. Wichman, C. S.,
    4. Allingham, R. R.,
    5. Hauser, M. A. and
    6. Ahmad, I.
    (2017b). Modeling glaucoma: retinal ganglion cells generated from induced pluripotent stem cells of patients with SIX6 risk allele show developmental abnormalities. Stem Cells 35, 2239-2252. doi:10.1002/stem.2675
    OpenUrlCrossRef
  65. ↵
    1. Wang, X.-W.,
    2. Li, Q.,
    3. Liu, C.-M.,
    4. Hall, P. A.,
    5. Jiang, J.-J.,
    6. Katchis, C. D.,
    7. Kang, S.,
    8. Dong, B. C.,
    9. Li, S. and
    10. Zhou, F.-Q.
    (2018). Lin28 signaling supports mammalian PNS and CNS axon regeneration. Cell Rep. 24, 2540-2552.e2546. doi:10.1016/j.celrep.2018.07.105
    OpenUrlCrossRef
  66. ↵
    1. Xia, X.,
    2. Teotia, P. and
    3. Ahmad, I.
    (2018). Lin28a regulates neurogliogenesis in mammalian retina through the Igf signaling. Dev. Biol. 440, 113-128. doi:10.1016/j.ydbio.2018.05.007
    OpenUrlCrossRef
  67. ↵
    1. Yadav, A.,
    2. Kalita, A.,
    3. Dhillon, S. and
    4. Banerjee, K.
    (2005). JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J. Biol. Chem. 280, 31830-31840. doi:10.1074/jbc.M501316200
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Zuber, M. E.,
    2. Gestri, G.,
    3. Viczian, A. S.,
    4. Barsacchi, G. and
    5. Harris, W. A.
    (2003). Specification of the vertebrate eye by a network of eye field transcription factors. Development 130, 5155-5167. doi:10.1242/dev.00723
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Zukor, K.,
    2. Belin, S.,
    3. Wang, C.,
    4. Keelan, N.,
    5. Wang, X. and
    6. He, Z.
    (2013). Short hairpin RNA against PTEN enhances regenerative growth of corticospinal tract axons after spinal cord injury. J. Neurosci. 33, 15350-15361. doi:10.1523/JNEUROSCI.2510-13.2013
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

Keywords

 Download PDF

Email
HUMAN DEVELOPMENT
Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway
Pooja Teotia, Matthew J. Van Hook, Dietmar Fischer, Iqbal Ahmad
Development 2019 146: dev178012 doi: 10.1242/dev.178012 Published 4 July 2019
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Subject collections

Other journals from The Company of Biologists

Advertisement

Development presents...

Following on from the success of our virtual Development Meeting 2020, we’re excited to announce the launch of a new and interactive developmental biology webinar series.

Author choices on Development: how ‘open’ are we to Open Access?

Read our Editorial about Development becoming a Transformative Journal and the changes we’re making to ensure that all authors can publish with us, irrespective of financial status or funder Open Access mandates.

The people behind the papers – Awais Javed and Michel Cayouette

In an interview, PhD student Awais Javed and his supervisor Michel Cayouette talk about their new retinal development paper, the impact of COVID-19 on their research and away from the bench.

New trends in cellular therapy

Hideyuki Okano and Doug Sipp summarise the use of pluripotent stem cells for regenerative therapy and the influence of developmental biology-inspired approaches, in their new Spotlight Article.

Development and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.